 U.S. marketing application filing for Cidara Therapeutics Incs NASDAQ: CDTX rezafungin remains on track for mid-2022, setting up a potential early 2023 approval and launch. Cidara confirmed that the application filing of lead antifungal drug rezafungin as a potential first-. 